| Literature DB >> 34017760 |
Sarika P Kombade1, Kumar S Abhishek2, Payal Mittal3, Charu Sharma4, Pratibha Singh4, Vijaya L Nag1.
Abstract
INTRODUCTION: Vulvovaginal candidiasis (VVC) is the commonest form of sexually transmitted infection especially in sexually active females. Various species of Candida i.e., Candida albicans and non-albicans Candida are associated with VVC. More than 75% of women experiences vulvovaginal candidiasis at least once in their lifetime and 10% of it can lead to recurrent VVC. So, this study was planned to evaluate the clinico-mycological profile and antifungal profile of VVC in sexually active female attending tertiary care hospital.Entities:
Keywords: Antifungal profile; Candida species; conventional method; vulvovaginal candidiasis
Year: 2021 PMID: 34017760 PMCID: PMC8132794 DOI: 10.4103/jfmpc.jfmpc_1124_20
Source DB: PubMed Journal: J Family Med Prim Care ISSN: 2249-4863
Figure 1Gram's Staining of the high vaginal swab showing Gram positive budding yeast cells (Arrow head)
Colour produced on Chromagar by different Candida species.
| Colony Colour | |
|---|---|
| Light green | |
| Pale green | |
| White to cream | |
| Blue with pink halo | |
| Purple, fuzzy | |
| Cream to white | |
| Cream to white with slight purple centre |
Figure 2Colour produced on Candida CHROMagar. a. C. tropicalis; b. C. albicans, c. C. krusei, d. C. glabrata, e. C. kefyr
Figure 3a. Gram's Stain of isolate showing budding yeast cells (Arrow head); b. Germ tube formation test (Arrow head); c. Morphology on Corm Meal agar (Dalmau's method)
Interpretive breakpoints of MIC adopted in the present study
| Antifungal agent | Susceptible | Susceptible-dose dependent | Resistant |
|---|---|---|---|
| Fluconazole | ≤8 µg/ml | 16 µg/ml≤ MIC ≤32 µg/ml | ≥64 µg/ml |
| Voriconazole | ≤0.125 µg/ml | - | ≥0.5 µg/ml |
| Itraconazole | ≤0.125 µg/ml | 0.25 µg/ml≤ MIC ≤0.5 µg/ml | ≥1 µg/ml |
| Amphotericin B | ≤1 µg/ml | NA | >1 µg/ml |
MIC: Minimum Inhibitory Concentration; NA: Not Applicable
Figure 4Age wise distribution of cases
Figure 5Symptoms wise distribution of cases
Figure 6Distribution of various Candida species
Antifungal resistance of Candidial isolates (n=26)
| Drugs | Total | |||||
|---|---|---|---|---|---|---|
| Amphotericin B | 0 | 8 (53.33) | 0 | 0 | 1 (100) | 9 (34.62) |
| Itraconazole | 4 (80) | 12 (80) | 2 (66.67) | 2 (100) | 1 (100) | 21 (80.77) |
| Fluconazole | 1 (20) | 4 (26.67) | 0 | 2 (100) | 1 (100)* | 8 (30.77) |
| Voriconazole | 0 | 5 (33.33) | 0 | 1 (50) | 0 | 6 (23.08) |
*Candida krusei is intrinsically resistant to Fluconazole. (CLSI)